middle.news
Alterity Therapeutics Accelerates MSA Drug Development with FDA Fast Track Nod
3:23am on Monday 2nd of June, 2025 AEST
•
Healthcare
Read Story
Alterity Therapeutics Accelerates MSA Drug Development with FDA Fast Track Nod
3:23am on Monday 2nd of June, 2025 AEST
Key Points
FDA grants Fast Track designation to ATH434 for Multiple System Atrophy
Phase 2 trial data shows clinically meaningful efficacy and safety
Fast Track enables more frequent FDA interactions and rolling review
ATH434 acts as an iron chaperone targeting α-synuclein pathology
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Alterity Therapeutics (ASX:ATH)
OPEN ARTICLE